High-risk myeloma is associated with global elevation of miRNAs and overexpression of EIF2C2/AGO2
暂无分享,去创建一个
David R Williams | Bart Barlogie | O. Stephens | B. Barlogie | J. Shaughnessy | E. Anaissie | F. van Rhee | David R. Williams | M. Pineda‐Roman | Y. Alsayed | Lijuan Chen | Yiming Zhou | Xiaosong Wu | Frits van Rhee | Yiming Zhou | Elias Anaissie | Mauricio Pineda-Roman | John D Shaughnessy | Xiaosong Wu | Owen Stephens | Bijay Nair | Sarah Waheed | Yazan Alsayed | Lijuan Chen | Marie-Astrid Cartron | S. Waheed | B. Nair | M. Cartron
[1] M. Czech. MicroRNAs as therapeutic targets. , 2006, The New England journal of medicine.
[2] Jan-Fang Cheng,et al. Dicer, Drosha, and outcomes in patients with ovarian cancer. , 2008, The New England journal of medicine.
[3] D. Lavelle,et al. Histone deacetylase inhibitors increase p21WAF1 and induce apoptosis of human myeloma cell lines independent of decreased IL‐6 receptor expression , 2001, American journal of hematology.
[4] Jörg Hackermüller,et al. Interleukin-6 dependent survival of multiple myeloma cells involves the Stat3-mediated induction of microRNA-21 through a highly conserved enhancer. , 2007, Blood.
[5] B. Barlogie,et al. Correlation of TACC3, FGFR3, MMSET and p21 expression with the t(4;14)(p16·3;q32) in multiple myeloma , 2004, British journal of haematology.
[6] F. Slack,et al. Inhibiting microRNA function in vivo. , 2009 .
[7] Kathryn A. O’Donnell,et al. c-Myc-regulated microRNAs modulate E2F1 expression , 2005, Nature.
[8] E. Wiemer,et al. miRNAs and cancer , 2006, Journal of RNAi and gene silencing : an international journal of RNA and gene targeting research.
[9] Stijn van Dongen,et al. miRBase: tools for microRNA genomics , 2007, Nucleic Acids Res..
[10] C. Croce,et al. MicroRNA profiling as a tool to understand prognosis, therapy response and resistance in breast cancer. , 2008, European journal of cancer.
[11] D. Melton,et al. "Stemness": Transcriptional Profiling of Embryonic and Adult Stem Cells , 2002, Science.
[12] John Crowley,et al. The molecular classification of multiple myeloma. , 2006, Blood.
[13] C. Croce,et al. MicroRNAs in the pathogeny of chronic lymphocytic leukaemia , 2007, British journal of haematology.
[14] D. Haber,et al. Dual Role for Argonautes in MicroRNA Processing and Posttranscriptional Regulation of MicroRNA Expression , 2007, Cell.
[15] N. Rajewsky,et al. Silencing of microRNAs in vivo with ‘antagomirs’ , 2005, Nature.
[16] B. Barlogie,et al. Poor prognosis in multiple myeloma is associated only with partial or complete deletions of chromosome 13 or abnormalities involving 11q and not with other karyotype abnormalities. , 1995, Blood.
[17] D. Bartel. MicroRNAs Genomics, Biogenesis, Mechanism, and Function , 2004, Cell.
[18] T. Golub,et al. Impaired microRNA processing enhances cellular transformation and tumorigenesis , 2007, Nature Genetics.
[19] K. Tarte,et al. Generation of polyclonal plasmablasts from peripheral blood B cells: a normal counterpart of malignant plasmablasts. , 2002, Blood.
[20] Charles P. Lin,et al. MicroRNAs 15a and 16 regulate tumor proliferation in multiple myeloma. , 2009, Blood.
[21] K. Tarte,et al. Gene expression profiling of plasma cells and plasmablasts: toward a better understanding of the late stages of B-cell differentiation. , 2003, Blood.
[22] A. Hatzigeorgiou,et al. TarBase: A comprehensive database of experimentally supported animal microRNA targets. , 2005, RNA.
[23] R. Tibshirani,et al. Significance analysis of microarrays applied to the ionizing radiation response , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[24] C. Croce,et al. MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis , 2008, Proceedings of the National Academy of Sciences.
[25] C. Croce,et al. MicroRNA signatures in human cancers , 2006, Nature Reviews Cancer.
[26] J. Doudna,et al. A three-dimensional view of the molecular machinery of RNA interference , 2009, Nature.
[27] Pablo Tamayo,et al. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[28] Tsung-Cheng Chang,et al. Widespread microRNA repression by Myc contributes to tumorigenesis , 2008, Nature Genetics.
[29] B. Barlogie,et al. High incidence of chromosome 13 deletion in multiple myeloma detected by multiprobe interphase FISH. , 2000, Blood.
[30] J. M. Thomson,et al. Argonaute2 Is the Catalytic Engine of Mammalian RNAi , 2004, Science.
[31] Yongsheng Huang,et al. A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. , 2006, Blood.
[32] C. Croce,et al. MicroRNAs in the ontogeny of leukemias and lymphomas , 2009, Leukemia & lymphoma.
[33] Anton J. Enright,et al. A Slicer-independent role for Argonaute 2 in hematopoiesis and the microRNA pathway. , 2007, Genes & development.
[34] L. Platanias,et al. Growth inhibition of a human myeloma cell line by all-trans retinoic acid is not mediated through downregulation of interleukin-6 receptors but through upregulation of p21(WAF1). , 1999, Blood.
[35] P. Brown,et al. Large-scale meta-analysis of cancer microarray data identifies common transcriptional profiles of neoplastic transformation and progression. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[36] G. Tsongalis,et al. MicroRNAs: novel biomarkers for human cancer. , 2009, Clinical chemistry.
[37] A. Neri,et al. Integrative high‐resolution microarray analysis of human myeloma cell lines reveals deregulated miRNA expression associated with allelic imbalances and gene expression profiles , 2009, Genes, chromosomes & cancer.